The schizophrenia paradigm: A hundred-year challenge

Journal of Nervous and Mental Disease

Volumn 194, Issue 9, 2006, Pages 639-643

  Carpenter Jr , William T ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

CATATONIA; DRUG RESPONSE; EDITORIAL; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HEBEPHRENIA; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; PARANOIA; PHENOTYPE; PSYCHOSIS; SCHIZOPHRENIA;

HISTORY, 20TH CENTURY; HUMANS; MODELS, NEUROLOGICAL; MODELS, PSYCHOLOGICAL; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYNDROME;

EID: 33748802757     PISSN: 00223018     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nmd.0000235484.45810.df     Document Type: Editorial

References (62)

1. Amador XF, Kirkpatrick B, Buchanan RW, Carpenter WT, Marcinko L, Yale SA (1999) Stability of the diagnosis of deficit syndrome in schizophrenia. Am J Psychiatry. 156:637-639.
2. Arango C, Adami H, Sherr JD, Thaker GK, Carpenter WT (1999) Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. Am J Psychiatry. 156:1097-1099.
3. Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT (2004) The deficit syndrome in schizophrenia: Implications for the treatment of negative symptoms. Eur Psychiatry. 19:21-26.
4. Bleuler E (1911/1950) In J Zinkin (Trans), Dementia Praecox or the Group of Schizophrenias. New York: International Universities Press.
5. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 151:20-26.
6. Buchanan RW, Ball MP, Weiner E, Kirkpatrick B, Gold JM, McMahon RP, Carpenter WT Jr (2005) Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry. 162:124-129.
7. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 155:751-760.
8. Buchanan RW, Breier A, Kirkpatrick B, Elkashef A, Munson RC, Gellad F, Carpenter WT (1993) Structural abnormalities in deficit vs. nondeficit schizophrenia. Am J Psychiatry. 150:59-65.
9. Buchanan RW, Carpenter WT (1994) Domains of psychopathology: An approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis. 182:193-204.
10. Buchanan RW, Kirkpatrick B, Heinrichs DW, Carpenter WT (1990) Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry. 147:290-294.
11. Buchanan RW, Strauss ME, Breier A, Kirkpatrick B, Carpenter WT (1997) Attentional impairments in deficit and nondeficit forms of schizophrenia. Am J Psychiatry. 154:363-370.
12. Buchanan RW, Strauss ME, Kirkpatrick B, Holstein C, Breier A, Carpenter WT (1994) Neuropsychological impairments in deficit vs. nondeficit forms of schizophrenia. Arch Gen Psychiatry. 51:804-811.
13. Bustillo JR, Thaker G, Buchanan RW, Moran M, Kirkpatrick B, Carpenter WT (1997) Visual information-processing impairments in deficit and nondeficit schizophrenia. Am J Psychiatry. 154:647-654.
14. Carpenter WT (1992) The negative symptom challenge. Arch Gen Psychiatry. 49:236-237.
15. Carpenter WT (2004) Clinical constructs and therapeutic discovery. Schizophr Res. 72:69-73.
16. Carpenter WT, Arango C, Buchanan RW, Kirkpatrick B (1999a) Deficit psychopathology and a paradigm shift in schizophrenia research. Biol Psychiatry. 46:352-360.
17. Carpenter WT, Bartko JJ, Strauss JS, Hawk AB (1978) Signs and symptoms as predictors of outcome: A report from the International Pilot Study of Schizophrenia. Am J Psychiatry. 135:940-945.
18. Carpenter WT, Buchanan RW (1989) Domains of psychopathology relevant to the study of etiology and treatment of schizophrenia. In SC Schulz, CT Tamminga (Eds), Schizophrenia: Scientific Progress (pp 13-22). New York: Oxford University Press.
19. Carpenter WT, Buchanan RW (1994) Schizophrenia. N Eng J Med. 330:681-690.
20. Carpenter WT, Buchanan RW, Kirkpatrick B, Tamminga CA, Wood F (1993) Strong inference, theory falsification and the neuroanatomy of schizophrenia. Arch Gen Psychiatry. 50:825-831.
21. Carpenter WT, Conley RR, Buchanan RW, Breier A, Tamminga CA (1995) Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry. 152:827-832.
22. Carpenter WT, Gold JM (2002) Another view of therapy for cognition in schizophrenia (Editorial). Biol Psychiatry. 52:969-971.
23. Carpenter WT, Heinrichs DW, Wagman AMI (1988) Deficit and non-deficit forms of schizophrenia: The concept. Am J Psychiatry. 145:578-583.
24. Carpenter WT, Kirkpatrick B, Buchanan RW (1999b) Schizophrenia: Syndromes and diseases. J Psychiatr Res. 33:473-475.
25. Carpenter WT, Stephens JH (1982) Prognosis as the critical variable in classification of the functional psychoses. J Nerv Ment Dis. 170:688-691.
26. Carpenter WT, Strauss JS (1974) Cross-cultural evaluation of Schneider's first rank symptoms of schizophrenia: A report from the International Pilot Study of Schizophrenia. Am J Psychiatry. 131:682-687.
27. Carpenter WT, Strauss JS (1991) The prediction of outcome in schizophrenia, IV: Eleven-year follow-up of the Washington IPSS cohort. J Nerv Ment Dis. 179:517-525.
28. Carpenter WT, Strauss JS, Bartko JJ (1973b) A flexible system for the identification of schizophrenia: A report from the International Pilot Study of Schizophrenia. Science. 182:1275-1278.
29. Carpenter WT, Strauss JS, Bartko JJ (1981) Beyond diagnosis: The phenomenology of schizophrenia. Am J Psychiatry. 138:948-953.
30. Carpenter WT, Strauss JS, Muleh S (1973a) Are there pathognomonic symptoms in schizophrenia? An empiric investigation of Kurt Schneider's first rank symptoms. Arch Gen Psychiatry. 28:847-852.
31. Erhart SM, Marder SR, Carpenter WT (2006) Treatment of schizophrenia negative symptoms: Future prospects. Schizophr Bull. 32:234-237.
32. Hawk AB, Carpenter WT, Strauss JS (1975) Diagnostic criteria and 5-year outcome in schizophrenia: A report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry. 32:343-356.
33. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT (1989) The Schedule for the Deficit Syndrome: An instrument for research in schizophrenia. Psychiatry Res. 30:119-123.
34. Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT (1993) Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res. 47:47-56.
35. Kirkpatrick B, Buchanan RW, Breier AB, Carpenter WT (1994) Depressive symptoms and the deficit syndrome of schizophrenia. J Nerv Ment Dis. 182:452-455.
36. Kirkpatrick B, Carpenter WT (1995) Drug development & the deficit syndrome of schizophrenia (Editorial). Biol Psychiatry. 38:277-278.
37. Kirkpatrick B, Amador XF, Flaum M, Yale SA, Gorman JM, Carpenter WT, Tohen M, McGlashan T (1996) The deficit syndrome in the DSM-IV Field Trial, I: Alcohol and other drug abuse. Schizophr Res. 20:69-77.
38. Kirkpatrick B, Kopelowicz A, Buchanan RW, Carpenter WT (2000a) Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology. 22:303-310.
39. Kirkpatrick B, Castle D, Murray RM, Carpenter WT (2000b) Risk factors for the deficit syndrome of schizophrenia. Schizophr Bull. 26:233-42.
40. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT (2001) A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 58:165-171.
41. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 32:214-219.
42. Kraepelin E (1893/1971) In RM Barclay (Trans), Dementia Praecox and Paraphrenia. Huntington (NY): Robert E. Kreiger.
43. Langfeldt G (1937) The Prognosis in Schizophrenia and the Factors Influencing the Course of the Disease. Copenhagen: E. Munksgaard.
44. Langfeldt G (1939) The Schizophrenic States. Copenhagen: E. Munksgaard.
45. Messias E, Kirkpatrick B, Bromet E, Ross D, Buchanan RW, Carpenter WT, Tek C, Kendler KS, Walsh D, Dollfus S (2004) Summer birth and deficit schizophrenia: A pooled analysis from 6 countries. Arch Gen Psychiatry. 61:985-989.
46. Schneider K (1959) In Hamilton (Trans), Clinical Psychopathology. New York: Grune & Stratton, Inc.
47. Spitzer RL, Endicott J, Robins E (1975) Research diagnostic criteria. Psychopharmacol Bull. 11:22-25.
48. Stephens JH, Ota KY, Carpenter WT, Shaffer JW (1980) Diagnostic criteria for schizophrenia: Prognostic implications and diagnostic overlap. Psychiatry Res. 2:1-12.
49. Strauss JS, Carpenter WT (1971) The prediction of outcome in schizophrenia, I: Characteristics of outcome. Arch Gen Psychiatry. 27:2-28.
50. Strauss JS, Carpenter WT (1974a) Characteristic symptoms and outcome in schizophrenia. Arch Gen Psychiatry. 30:117-120.
51. Strauss JS, Carpenter WT (1974b) The prediction of outcome in schizophrenia, II: Relationships between predictor and outcome variables: a report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry. 31:37-42.
52. Strauss JS, Carpenter WT Jr, Bartko JJ (1974c) The diagnosis and understanding of schizophrenia, part III: Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull. Winter;11:61-69.
53. Strauss JS, Carpenter WT (1977) Prediction of outcome in schizophrenia, III: Five-year outcome and its predictors: A report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry. 34:159-163.
54. Strauss JS, Carpenter WT (1978) The prognosis of schizophrenia: Rationale for a multi-dimensional concept. Schizophr Bull. 4:56-67.
55. Strauss JS, Bartko JJ, Carpenter WT (1981) New directions in diagnosis: The longitudinal processes of schizophrenia. Am J Psychiatry. 138:954-958.
56. Summerfelt AT, Buchanan RW, Breier A, Bryant N, Strauss ME (1995) The relationships of cerebellar vermis morphology to neuropsychological functions in schizophrenia and normal controls. Schizophr Res. 15:136.
57. Tamminga CA, Thaker GK, Buchanan RW, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT (1992) Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry. 49:522-530.
58. Wagman AMI, Heinrichs DW, Carpenter WT (1987) The deficit and nondeficit forms of schizophrenia: Neuropsychological evaluation. Psychiatry Res. 22:319-330.
59. Waltrip RW, Buchanan RW, Carpenter WT, Kirkpatrick B, Summerfelt A, Breier A, Rubin SA, Carbone KM (1997) Borna disease virus antibodies and the deficit syndrome of schizophrenia. Schizophr Res. 23:253-257.
60. World Health Organization (Ed) (1974) Co-authored by collaborating investigators, Report of the International Pilot Study of Schizophrenia (Vol 1). Geneva, Switzerland: WHO Press.
61. Summary version (150 pp) published in four languages, World Health Organization (Eds) (1978) Schizophrenia: a Multinational Study. Geneva, Switzerland.
62. World Health Organization (Ed) (1978) Co-authored by collaborating investigators, Report of the International Pilot Study of Schizophrenia (Vol 2). Geneva, Switzerland: WHO Press.